(Q45783219)

16 December 2017

title

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes (English)

1 reference

16 December 2017

1 reference

1 reference

placebo-controlled trial

1 reference

6

1 reference

16 December 2017

Barbara Savarese

4

object named as

B Savarese

1 reference

16 December 2017

author name string

S E Straus

1

1 reference

16 December 2017

L Corey

2

1 reference

16 December 2017

R L Burke

3

1 reference

16 December 2017

G Barnum

5

1 reference

16 December 2017

R G Kost

7

1 reference

16 December 2017

J L Meier

8

1 reference

16 December 2017

R Sekulovich

9

1 reference

16 December 2017

S F Adair

10

1 reference

16 December 2017

language of work or name

English

0 references

publication date

1 June 1994

1 reference

16 December 2017

published in

The Lancet

1 reference

16 December 2017

volume

343

1 reference

16 December 2017

issue

8911

1 reference

16 December 2017

page(s)

1460-1463

1 reference

16 December 2017

Prospects for the control of AIDS by immunizing seropositive individuals

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Risk Factors for the Sexual Transmission of Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

VACCINE THERAPY IN RECURRENT HERPES SIMPLEX

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Herpes simplex virus glycoprotein treatment of recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Herpes Simplex Virus Type-2 Glycoprotein-Subunit Vaccine: Tolerance and Humoral and Cellular Responses in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

An analysis of the biological properties of monoclonal antibodies against glycoprotein D of herpes simplex virus and identification of amino acid substitutions that confer resistance to neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Overlapping T cell antigenic sites on a synthetic peptide fragment from herpes simplex virus glycoprotein D, the degenerate MHC restriction elicited, and functional evidence for antigen-Ia interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992581-X

7 January 2021

10.1016/S0140-6736(94)92581-X

Identifiers

DOI

1 reference

16 December 2017

release_7trolqnvebau7fdblbluim73mu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7trolqnvebau7fdblbluim73mu

24 November 2022

mapped directly with Wikidata item

PubMed ID

7911177

1 reference

16 December 2017